Globeflex Capital’s Akebia Therapeutics AKBA Stock Holding History

Globeflex Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-40	Closed	–	–	499
2015 Q2	$0	Buy	+40	New	+$341	﹤0.01%	503

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Globeflex Capital's AKBA Position: Q3 2015 in Review

Globeflex Capital sold out of Akebia Therapeutics (AKBA) in Q3 2015, closing a stake of 40 shares.

Globeflex Capital first reported a position in AKBA in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 82 funds tracked by Wall St. Rank hold AKBA as of Q3 2015.

Globeflex Capital reported no remaining Akebia Therapeutics position as of Q3 2015 after selling out during the quarter.
Globeflex Capital sold 40 Akebia Therapeutics shares in Q3 2015.
Globeflex Capital first reported a position in Akebia Therapeutics in Q2 2015 and held it in 1 quarter.
Globeflex Capital's Akebia Therapeutics position peaked at $0 in Q2 2015.
82 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2015.

Based on Globeflex Capital's 13F filing for Q3 2015, filed 9 Nov 2015.